Investigation of Glucose Metabolism by Continuous Glucose Monitoring and Validation of Dipeptidyl Peptidase 4 Inhibitor Use in Patients with Myotonic Dystrophy Type 1

被引:1
作者
Takada, Hiroto [1 ]
Matsumura, Tsuyoshi [2 ]
Shimamura, Haruna [3 ]
Matsui, Misa [2 ]
Kon, Seiko [1 ]
Fukumoto, Aono [3 ]
Kubota, Tomoya [3 ]
Yoshida, Kosuke [4 ]
Iwahashi, Hiromi [5 ]
Takahashi, Masanori P. [3 ]
机构
[1] NHO Aomori Natl Hosp, Dept Neurol, Aomori 0381331, Japan
[2] NHO Osaka Toneyama Med Ctr, Dept Neurol, Toyonaka, Osaka 5608552, Japan
[3] Osaka Univ, Grad Sch Med, Dept Clin Lab & Biomed Sci, Clin Neurophysiol, Suita, Osaka 5650871, Japan
[4] NHO Asahikawa Med Ctr, Dept Neurol, Asahikawa, Hokkaido 0708644, Japan
[5] Toyonaka City Hosp, Dept Internal Med, Toyonaka, Osaka 5608565, Japan
关键词
incretin; teneligliptin; hypoglycemia; myotonic dystrophy; diabetes; BLOOD-GLUCOSE; HYPOGLYCEMIA; PROFILE;
D O I
10.3390/jcm13175252
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: We characterized blood glucose fluctuations in patients with myotonic dystrophy type 1 (DM1). After confirming the incretin secretion capacity of patients with DM1, we intended to clarify whether dipeptidyl peptidase 4 (DPP-4) inhibitor administration was appropriate in cases of DM1 with diabetes mellitus. Methods: A 48 h continuous glucose monitoring (CGM) was performed in 29 Japanese patients with DM1. An oral glucose tolerance test (OGTT) was performed in patients with DM1 and five disease controls, and levels of blood glucose, insulin, and incretin (glucagon-like peptide-1 and gastric inhibitory polypeptide) were measured. DPP-4 inhibitors were administered to patients with diabetes mellitus complicated by DM1, and the CGM results were compared. Results: The CGM showed distinct patterns of blood glucose variability among patients classified by an OGTT pattern with significant differences in glucose parameters such as time above 140 mg/dL and mean amplitude of glycemic excursions between the groups. High sensor glucose values were observed in a certain number of patients who were classified as having normal or impaired glucose tolerance by the OGTT. The CGM confirmed the presence of low glucose levels in several patients. Incretin secretion, the target of DPP-4 inhibitors, was preserved in patients with DM1. DPP-4 inhibitor treatment resulted in lower glucose levels and improved insulin secretion in some patients. Conclusions: This is the first CGM study for DM1 patients. The CGM identified potential early abnormalities in glucose metabolism in DM1. In the future, it will be crucial to explore effective methods for harnessing CGM and assessing it quantitatively in DM1.
引用
收藏
页数:11
相关论文
共 50 条
[41]   Indication of CGMS (Continuous Glucose Monitoring System) in the functionnal investigations of adult type 1 diabetic patients [J].
Melki, V ;
Hanaire-Broutin, H .
DIABETES & METABOLISM, 2001, 27 (05) :618-623
[42]   Benefits and Barriers of Continuous Glucose Monitoring in Young Children with Type 1 Diabetes [J].
Hilliard, Marisa E. ;
Levy, Wendy ;
Anderson, Barbara J. ;
Whitehouse, Amanda L. ;
Commissariat, Persis, V ;
Harrington, Kara R. ;
Laffel, Lori M. ;
Miller, Kellee M. ;
Van Name, Michelle ;
Tamborlane, William, V ;
DeSalvo, Daniel J. ;
DiMeglio, Linda A. .
DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 (09) :493-498
[43]   Continuous glucose monitoring use and glucose variability in pre-school children with type 1 diabetes [J].
Dovc, Klemen ;
Cargnelutti, Kevin ;
Sturm, Anze ;
Selb, Julij ;
Bratina, Natasa ;
Battelino, Tadej .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 147 :76-80
[44]   Caregiver satisfaction with the use of continuous glucose monitoring and flash glucose monitoring in very young children with type 1 diabetes [J].
Aouchiche, Karine ;
Bernoux, Delphine ;
Sadoul, Elisabeth Baechler ;
Haine, Elsa ;
Joubert, Florence ;
Epstein, Sophie ;
Galon, Noemie Faure ;
Dalla-Vale, Fabienne ;
Combe, Jean-Charles ;
Samper, Martine ;
Simonin, Gilbert ;
Castets, Sarah ;
Marquant, Emeline ;
Vergier, Julia ;
Reynaud, Rachel .
ARCHIVES DE PEDIATRIE, 2025, 32 (01) :36-40
[45]   The dipeptidyl peptidase-4 inhibitor linagliptin lowers postprandial glucose and improves measures of β-cell function in type 2 diabetes [J].
Heise, T. ;
Larbig, M. ;
Patel, S. ;
Seck, T. ;
Hehnke, U. ;
Woerle, H. -J. ;
Dugi, K. .
DIABETES OBESITY & METABOLISM, 2014, 16 (10) :1036-1039
[46]   Hypoglycemia in blood glucose level in type 2 diabetic Japanese patients by continuous glucose monitoring [J].
Hajime, Maiko ;
Okada, Yosuke ;
Mori, Hiroko ;
Uemura, Fumi ;
Sonoda, Satomi ;
Tanaka, Kenichi ;
Kurozumi, Akira ;
Narisawa, Manabu ;
Torimoto, Keiichi ;
Tanaka, Yoshiya .
DIABETOLOGY & METABOLIC SYNDROME, 2019, 11 (1)
[47]   Hypoglycemia in blood glucose level in type 2 diabetic Japanese patients by continuous glucose monitoring [J].
Maiko Hajime ;
Yosuke Okada ;
Hiroko Mori ;
Fumi Uemura ;
Satomi Sonoda ;
Kenichi Tanaka ;
Akira Kurozumi ;
Manabu Narisawa ;
Keiichi Torimoto ;
Yoshiya Tanaka .
Diabetology & Metabolic Syndrome, 11
[48]   Effect of structured individualized education on continuous glucose monitoring use in poorly controlled patients with type 1 diabetes: A randomized controlled trial [J].
Yoo, Jee Hee ;
Kim, Gyuri ;
Lee, Hyun Jung ;
Sim, Kang Hee ;
Jin, Sang-Man ;
Kim, Jae Hyeon .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 184
[49]   A systematic review: Cost-effectiveness of continuous glucose monitoring compared to self-monitoring of blood glucose in type 1 diabetes [J].
Jiao, Yuxin ;
Lin, Rose ;
Hua, Xinyang ;
Churilov, Leonid ;
Gaca, Michele J. ;
James, Steven ;
Clarke, Philip M. ;
O'Neal, David ;
Ekinci, Elif, I .
ENDOCRINOLOGY DIABETES & METABOLISM, 2022, 5 (06)